Test Price
600 AED✅ Home Collection Available
Estrogen Receptor (ER) & Progesterone Receptor (PR) IHC Test in UAE | 600 AED | DNA Labs UAE
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – ISO 9001:2015 accredited immunohistochemistry with automated digital quantification (Allred/H-Score).
- Specialist Logistics – Secure Medical Courier Solid Tissue Specimen Retrieval from any accredited UAE hospital or clinic. Same-day pickup available daily from 8 AM to 11 PM.
- Post-Test Clinical Guidance – Complimentary telephonic interpretation of your ER/PR IHC report with a DHA-licensed Specialist Diagnostic Radiologist.
- Insurance & Billing – Direct billing verification and pre-approval via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The ER/PR IHC test quantitatively assesses estrogen receptor (ER) and progesterone receptor (PR) protein expression in breast cancer tissue using standardized immunohistochemistry. This test is the cornerstone for determining endocrine responsiveness and guiding adjuvant hormonal therapy in invasive breast carcinoma. In the UAE, our ISO‑certified laboratory delivers definitive results within 3–5 days from an FFPE tissue block, supporting oncologists, surgical pathologists, and specialists in personalised care.
Our automated platform employs FDA-approved primary antibodies (SP1 for ER, PgR 636 for PR) on a Bond‑III platform, ensuring rigorous consistency and eliminating manual scoring variability.
| Feature | DNA Labs UAE ER/PR IHC | Alternative Standard IHC |
|---|---|---|
| Precision & Accuracy | 99.9% sensitivity, ISO 9001:2015 validated, automated digital scoring (Allred/H‑score) | Variable inter‑laboratory agreement; manual semi‑quantitative scoring |
| Methodology | Fully automated IHC (Bond‑III) with FDA‑approved primary antibodies (SP1, PgR 636) | Manual or semi‑automated IHC, non‑standardised antibody clones |
| Turnaround Time | 3–5 Days incl. courier retrieval | 3–7 days, no home collection/logistics |
Physician Insight & Safety Protocols
“As a Specialist Diagnostic Radiologist, I interpret ER/PR IHC results within the full clinical context of imaging, histology, and patient history. A strong positive result reliably guides endocrine therapy, while a negative result in a young patient mandates prompt genetic counselling and multidisciplinary oncologic discussion. IHC is a powerful tool, but it must never be read in isolation.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Important Clinical Advisory
⚠️ Clinical Guidance & Medication Stewardship
ER/PR IHC results must be evaluated alongside complete histological grading, tumor staging, and genomic profiling. Do not alter or discontinue prescribed endocrine therapies (e.g., tamoxifen, aromatase inhibitors) based solely on IHC results without explicit instruction from your treating oncologist.
Exclusion Criteria & ER/PR Red Flags
- Insufficient invasive tumor cells (<100 cells) – test may be indeterminate; repeat biopsy is strongly recommended.
- Decalcified bone specimens (acid decalcification) may produce false‑negative ER/PR results; avoid if possible.
- ER‑negative / PR‑negative tumor in a premenopausal woman under 35 – immediate oncology referral for genetic counselling and aggressive treatment stratification.
- Prolonged cold‑ischaemic time (>1 hour) or improper formalin fixation may compromise antigenicity and result accuracy.
- If you experience sudden breast mass enlargement, skin ulceration, or severe pain while awaiting results, proceed to the nearest emergency department immediately.
Patient FAQ & Clinical Guidance
1. What is the ER/PR IHC test, and why do I need it?
The ER/PR IHC test measures estrogen and progesterone receptor proteins in your breast cancer tissue. It is essential for determining if your tumor is hormone-receptor-positive and predicts whether endocrine therapies, such as tamoxifen or aromatase inhibitors, will be effective in your treatment plan.
2. What sample is required for the ER/PR IHC test?
The test is performed on an existing Formalin-Fixed Paraffin-Embedded (FFPE) tissue block from your previous biopsy or surgery. DNA Labs UAE arranges a Secure Medical Courier Solid Tissue Specimen Retrieval from your hospital or clinic—no additional biopsy is needed.
3. How long does it take to get results?
Your ER/PR IHC results are typically delivered within 3–5 working days from the time the specimen reaches our ISO‑certified laboratory. A complimentary telephonic consultation is scheduled to explain your report in detail.
4. How accurate is the ER/PR IHC test at DNA Labs UAE?
Our fully automated IHC platform, combined with digital quantification (Allred/H‑score), delivers a diagnostic sensitivity of 99.9%, ensuring highly reliable and reproducible results for your clinical team.
5. Can the test be done if I am currently on hormone therapy?
Yes, the test can be performed while you are on hormone therapy. However, the treating oncologist must interpret the results in the context of your current medications. Do not stop or change your hormone therapy based on the IHC report alone—always consult your physician first.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
DNA Labs UAE strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data, including immunohistochemistry results and genomic information, are encrypted, securely stored, and never shared without explicit patient consent. Clinical safety and patient consent protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Our DHA-licensed facility (License No. 1143) located in Dubai Healthcare City ensures that all laboratory processes meet the highest standards of quality and confidentiality mandated by UAE law.
Clinical & Logistical Metadata
| Test Name | Estrogen Receptor (ER) & Progesterone Receptor (PR) Immunohistochemistry (IHC) |
| Price (AED) | 600 AED |
| Turnaround Time | 3–5 Working Days |
| Sample Type / Matrix | Archival Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block / Biopsy Slides |
| Methodology Used | Automated Immunohistochemistry (IHC) on Bond‑III Platform with Digital Quantification (Allred / H‑Score) |
| ICD-10-CM Code | C50.9 (Malignant neoplasm of breast, unspecified) |
| LOINC Code | 18456-1 (Estrogen receptor [Interpretation] in Tissue by Immune stain) |
| DHA Facility License & Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians